Zobrazeno 1 - 10
of 395
pro vyhledávání: '"J. Feger"'
Publikováno v:
American Journal of Public Health. 112:S850-S853
Autor:
Mara L. Becker, Gwenyth Fischer, Chi D. Hornik, Omar Alibrahim, Kelechi Iheagwara, Kamal Abulebda, Andora L. Bass, Katherine Irby, Anjali Subbaswamy, Elizabeth E. Zivick, Jill Sweney, Anne G. Stormorken, Erin E. Barker, Shruthi Mahadaveiah, Riad Lutfi, Michael C. McCrory, John M. Costello, Kate G. Ackerman, Jennifer C. Munoz-Pareja, Bryan J. Feger, J. Michael Dean, Daniel F. Hanley, Rachel G. Greenberg, Radhika Avadhani, Richard E. Thompson, Daniel K. Benjamin, Christoph P. Hornik, Kanecia O. Zimmerman
Publikováno v:
Journal of Pediatric Intensive Care.
Objectives This article observes the mean daily dose of fentanyl required for adequate sedation in critically ill, mechanically ventilated children randomized to receive dexmedetomidine or placebo. Methods We conducted Dexmedetomidine Opioid Sparing
Autor:
Angelique E. Boutzoukas, Rachel Olson, Mary Ann Sellers, Gwenyth Fischer, Chi D. Hornik, Omar Alibrahim, Kelechi Iheagwara, Kamal Abulebda, Andora L. Bass, Katherine Irby, Anjali Subbaswamy, Elizabeth E. Zivick, Jill Sweney, Anne G. Stormorken, Erin E. Barker, Riad Lutfi, Michael C. McCrory, John M. Costello, Kate G. Ackerman, Jennifer C. Munoz Pareja, J. Michael Dean, Nael Abdelsamad, Daniel F. Hanley, W. Andrew Mould, Karen Lane, Mary Stroud, Bryan J. Feger, Rachel G. Greenberg, P. Brian Smith, Daniel K. Benjamin, Christoph P. Hornik, Kanecia O. Zimmerman, Mara L. Becker
Publikováno v:
Contemporary Clinical Trials. 125:107067
Timely trial start-up is a key determinant of trial success; however, delays during start-up are common and costly. Moreover, data on start-up metrics in pediatric clinical trials are sparse. To expedite trial start-up, the Trial Innovation Network p
Autor:
Matthew A Schechter, Michael K H Hsieh, Linda W Njoroge, J Will Thompson, Erik J Soderblom, Bryan J Feger, Constantine D Troupes, Kathleen A Hershberger, Olga R Ilkayeva, Whitney L Nagel, Gina P Landinez, Kishan M Shah, Virginia A Burns, Lucia Santacruz, Matthew D Hirschey, Matthew W Foster, Carmelo A Milano, M Arthur Moseley, Valentino Piacentino, Dawn E Bowles
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104157 (2014)
The molecular differences between ischemic (IF) and non-ischemic (NIF) heart failure are poorly defined. A better understanding of the molecular differences between these two heart failure etiologies may lead to the development of more effective hear
Externí odkaz:
https://doaj.org/article/97d4172e41884dda9d397f4cdd8030bd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Sports Science and Medicine, Vol 16, Iss 1, Pp 69-76 (2017)
The purpose of the study was to examine the effect of high-intensity exercise and carbohydrate supplementation (CHO) on plasma visfatin. On 2 separate days, 10 sprint-trained males (age = 26.4 ± 5.3 yr; Ht = 1.77 ± 0.03 m; Wt = 78.78 ± 9.10 kg; BF
Autor:
Michael J. Watson, Chetan B. Patel, Matthew A. Schechter, Dawn E. Bowles, Kevin W. Southerland, Louis R. DiBernardo, Bryan J. Feger, Mani A. Daneshmand, Rajashree Mishra, Carmelo A. Milano, Joseph G. Rogers, Jacob N. Schroder, Maragatha Kuchibhatla
Publikováno v:
Journal of Cardiac Failure. 22:158-162
Background Although primary graft dysfunction (PGD) is a leading cause of mortality and morbidity early post-heart transplant, relatively little is known regarding mechanisms involved in PGD development. Methods and Results We examined the relationsh
Autor:
Joseph W Starnes, Bryan J Feger
Publikováno v:
Journal of Nutrition & Food Sciences.
Autor:
Marcus D. Darrabie, Bryan J. Feger, Rajashree Mishra, Danny O. Jacobs, Lucia Santacruz, Jose G. Mantilla
Publikováno v:
Cardiovascular Toxicology. 15:180-188
Heart failure is a common complication of doxorubicin (DOX) therapy. Previous studies have shown that DOX adversely impacts cardiac energy metabolism, and the ensuing energy deficiencies antedate clinical manifestations of cardiac toxicity. Brief exp